Skip to main content

Advertisement

Table 5 Statistical comparison of pertinent clinical parameters between subtype V patients treated with and without adjuvant chemotherapy.

From: Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization

  Molecular Subtype V Breast Cancer
  Adjuvant Rx No-Adjuvant Rx pvalues*
  Patient (n = 28) Patient (n = 12)  
Age at diagnosis      
< 50 yr 16 57.1% 5 41.7% 0.49
>= 50 yr 12 42.9% 7 58.3%  
TNM Path T      
1 14 50.0% 8 66.7% 0.14
2 14 50.0% 3 25.0%  
3 0 0.0% 0 0.0%  
4 0 0.0% 1 8.3%  
TNM Path N      
0 13 46.4% 7 58.3% 0.86
1 8 28.6% 4 33.3%  
2 5 17.9% 1 8.3%  
3 2 7.1% 0 0.0%  
TNM Path M      
0 28 100.0% 12 100.0%  
Positive Lymph Nodes      
0 13 46.4% 7 58.3% 0.86
1-3 8 28.6% 4 33.3%  
4-9 5 17.9% 1 8.3%  
> = 10 2 7.1% 0 0.0%  
TNM Stage      
I 7 25.0% 6 50.0% 0.34
II 14 50.0% 4 33.3%  
III 7 25.0% 2 16.7%  
Nuclear Grade      
1 4 14.3% 5 41.7% 0.17
2 13 46.4% 4 33.3%  
3 8 28.6% 2 16.7%  
Hormonal Therapy      
No 3 10.7% 2 16.7% 0.63
Yes 25 89.3% 10 83.3%  
Post-op Radiation Rx      
No 20 71.4% 9 75.0% 1.00
Yes 8 28.6% 3 25.0%  
  1. *: p values were determined by Fisher's exact test
  2. There was no difference in follow-up duration between two groups (median 10.4 vs. 9.2 years, p = 0.17 by Wilcoxon rank sum test)